ANI Pharmaceuticals, Inc. and its consolidated subsidiaries (ANI) operate as a diversified bio-pharmaceutical company.
The company is focused on developing, manufacturing, and commercializing innovative and high-quality therapeutics.
On September 16, 2024, the company completed its previously announced acquisition of Alimera Sciences, Inc., a Delaware corporation pursuant to the terms of the Agreement and Plan of Merger (the Merger Agreement), dated as of June 21, 2024, by and among the compan...
ANI Pharmaceuticals, Inc. and its consolidated subsidiaries (ANI) operate as a diversified bio-pharmaceutical company.
The company is focused on developing, manufacturing, and commercializing innovative and high-quality therapeutics.
On September 16, 2024, the company completed its previously announced acquisition of Alimera Sciences, Inc., a Delaware corporation pursuant to the terms of the Agreement and Plan of Merger (the Merger Agreement), dated as of June 21, 2024, by and among the company, Alimera and ANIP Merger Sub INC., a Delaware corporation and wholly owned subsidiary of the company. Pursuant to the Merger Agreement, Merger Sub merged with and into Alimera, with Alimera surviving the merger as a wholly owned subsidiary of the company. In connection with the acquisition, the company added two new products, ILUVIEN and YUTIQ, both of which are indicated for the treatment of certain chronic retinal diseases.
The company's three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, and one is located in East Windsor, New Jersey, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products that must be manufactured in a fully contained environment. The company has ceased operations at its subsidiary in Oakville, Ontario, Canada as of March 31, 2023, and the building was ultimately sold in March 2024. This action was part of ongoing initiatives to capture operational synergies following the company’s acquisition of Novitium Pharma LLC (‘Novitium’) in November 2021. The company has fully completed the transition of the products manufactured or packaged in Oakville to one of the three U.S.-based manufacturing sites.
On August 13, 2024, the company entered into a credit agreement with JPMorgan Chase Bank, N.A., as administrative agent, and the financial institutions party thereto as lenders (the New Credit Agreement).
The company has a commercial portfolio of 125 products with a wide variety of indications and a robust portfolio of pipeline products as of December 31, 2024. This portfolio is the result of internal research and development, acquisitions of businesses, acquisitions of Abbreviated New Drug Applications (ANDAs), New Drug Applications (NDAs), product rights, and entry into agreements to obtain the distribution rights for various products.
Strategy
The company’s overall strategy is enabled by an empowered, collaborative, and purposeful team with high performance-orientation that seeks to deliver on its purpose of ‘Serving Patients, Improving Lives’.
The company’s growth strategy is driven by the following key growth drivers: building a successful rare disease and brands segment; strengthening its Generics and Other segment through continued investment in the company’s generic research and development capability and increased focus on niche opportunities; and considering a variety of criteria in determining which products to develop.
Purified Cortrophin Gel
The company acquired the NDAs for Purified Cortrophin Gel (Repository Corticotropin Injection USP) (‘Cortrophin Gel’) and Cortrophin-Zinc in January 2016 and executed long-term supply agreements with a supplier of the company’s primary raw material for corticotrophin API, a supplier of corticotrophin API with whom the company have advanced the manufacture of commercial scale batches of API, and a Cortrophin Gel fill/finish contract manufacturer. On October 29, 2021, the FDA approved the company’s Supplemental New Drug Application (‘sNDA’) for Cortrophin Gel for the treatment of certain chronic autoimmune disorders, including acute exacerbations of multiple sclerosis (‘MS’) and rheumatoid arthritis (‘RA’), in addition to excess urinary protein due to nephrotic syndrome. Cortrophin Gel is an adrenocorticotropic hormone (‘ACTH’), also known as purified corticotropin. On January 24, 2022, the company announced the commercial launch of Cortrophin Gel in the U.S. as the company’s foundational Rare Disease asset.
Throughout 2023 and 2024, the company continued to build and invest in its Rare Disease infrastructure to support growth in new areas of opportunity, such as pulmonology, ophthalmology, and gout in the ACTH market. On October 2, 2023, the company announced FDA approval and commercial availability of a 1-mLvial of Cortrophin Gel, appropriate for adjunctive treatment of certain patients with acute gouty arthritis flares.
During the first quarter of 2024, ANI launched a targeted ophthalmology-focused sales force for Cortrophin Gel. The team has continued to gain momentum in ophthalmology, driving significant growth in the number of new patient starts during 2024. Importantly, the addition of Alimera expands the reach of the ophthalmology sales team and there will be significant overlap between high potential prescribers of Cortrophin Gel, ILUVIEN, and YUTIQ.
ILUVIEN and YUTIQ
ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg, was developed in the U.S. and internationally for the treatment of diabetic macular edema (‘DME’), a leading cause of severe vision loss and blindness, and certain international markets for chronic non-infectious uveitis affecting the posterior segment of the eye (‘NIU-PS’). Alimera acquired exclusive commercialization rights to YUTIQ (fluocinolone acetonide intravitreal implant) 0.18 mg, in May 2023 from EyePoint Pharmaceuticals, Inc. (‘EyePoint’) for the treatment and prevention of NIU-PS worldwide except for Europe, the Middle East, Africa, (known as ILUVIEN in Europe, the Middle East and Africa) and certain Asian countries, including China. ILUVIEN and YUTIQ are state-of-the-art sustained release intravitreal implants that respectively help patients maintain vision longer and reduce disease recurrence. ILUVIEN is being evaluated as baseline therapy in naïve or near naïve patients with early DME in combination with the current standard of care, anti-vascular endothelial growth factor (‘VEGF’) therapy in the NEW DAY clinical trial. YUTIQ is being further studied in the SYNCHRONICITY clinical trial, a prospective, open-label clinical trial evaluating the safety and efficacy of YUTIQ for the treatment and prevention of chronic NIU-PS and related intraocular inflammation.
Both ILUVIEN and YUTIQ treat patients by delivering a continuous microdose of the corticosteroid fluocinolone acetonide (‘FAc’) in the eye, for up to 36 months. ILUVIEN was developed internally by Alimera and initially to treat DME, a disease of the retina that affects individuals with Type 1 or Type 2 diabetes and can lead to severe vision loss and blindness. ILUVIEN is sold to treat DME only in the U.S. YUTIQ is sold to treat NIU-PS only in the U.S. In certain European and Middle Eastern countries, ILUVIEN is approved and commercialized to treat DME and to prevent relapse in recurrent NIU-PS, an inflammatory disease of the uveal tract, which is consisted of the iris, ciliary body and choroid, that can lead to severe vision loss and blindness. The company also has rights to commercialize ILUVIEN for NIU-PS in Africa.
ILUVIEN and YUTIQ are both intravitreal implants that are inserted into the back of the patient’s eye in non-surgical procedures employing devices with 25-gauge needles, which allow for a self-sealing wounds. ‘Intravitreal’ refers to the space inside the eye behind the lens that contains the jelly-like substance called vitreous. The implants, which are non-bioerodible, provide consistent delivery as a result of their constant surface area, permitting elution of FAc to the vitreous. The company calls this CONTINUOUS MICRODOSING. This delivery mechanism provides lower daily and aggregate exposure to corticosteroids than any other intraocular dosage forms available, which mitigates the typical risks associated with corticosteroid therapy. CONTINUOUS MICRODOSING delivery makes ILUVIEN and YUTIQ the only approved drug therapies for DME and NIU-PS that are designed to deliver consistent daily therapeutic levels of corticosteroid and reduce the recurrence of DME and uveitis for up to three years. Other therapies that physicians use to treat DME, such as anti-VEGF treatments and other corticosteroids, are acute (short-acting) therapies that provide a higher initial daily dose but then rapidly decline, requiring frequent reinjection by the physician to maintain an effective dose or reestablish the therapeutic effect after the disease has recurred.
FAc is a non-proprietary corticosteroid and the active compound in ILUVIEN (0.19mg) and YUTIQ (0.18mg). The company believe that corticosteroids provide the best option in the treatment of DME and NIU-PS because they reduce the inflammatory aspects of both diseases. ILUVIEN and YUTIQ deliver continuous daily sub-microgram levels of FAc in in vivo release kinetic studies for up to 36 months. ILUVIEN and YUTIQ are the only single injection therapies available to treat retinal diseases consistently every day for up to three years, which may allow patients to see better, longer, with fewer injections.
NEW DAY Clinical Trial
ILUVIEN continues to be underutilized in the treatment of DME and should be used much earlier in patients suffering from DME. With the NEW DAY clinical trial, the company intends to demonstrate the efficacy of ILUVIEN as baseline therapy in patients with early DME by comparing ILUVIEN to the current standard of care, anti-VEGF therapy.
In July 2020, Alimera announced the initiation of the company’s NEW DAY clinical trial, a multicenter, single masked, randomized, controlled trial designed to generate prospective data evaluating ILUVIEN as a baseline therapy in the treatment of DME and demonstrate its advantages over using the current standard of care of repeat anti-VEGF injections. The NEW DAY clinical trial was fully enrolled with 300 treatment-naïve, or almost naïve, DME patients in approximately 42 sites around the U.S. The company expects to share the clinical trial data in the second half of 2025.
Patients who meet the entry criteria have been randomized to receive either an ILUVIEN intravitreal implant or five injections of intravitreal aflibercept 2 mg at four-week intervals for the first 16 weeks as a loading dose. After the initial 16-week period, both treatment arms will be evaluated every four weeks and receive supplemental intravitreal injections of aflibercept 2 mg only as needed. Criteria for supplemental treatment is set by protocol and will be identical in both treatment arms. The planned treatment period in the trial is 18 months. Once the treatment period is concluded, patients will be given the option to participate in an open label extension trial for up to 42 months.
The primary outcome measure for the NEW DAY clinical trial is the mean number of supplemental aflibercept injections needed during the trial between treatment groups. Key secondary endpoints include mean best corrected visual acuity (‘BCVA’) score over time up to 18 months, time to first supplemental treatment, retinal thickness amplitude on optical coherence tomography (‘OCT’), and diabetic retinopathy scores. In addition, the trial will collect patient-reported outcome measures to evaluate the effect on patients’ quality of life and level of functioning. Exploratory endpoints will include neuronal functional measures and OCT imaging measures of retinal nerve layer thickness.
SYNCHRONICITY Clinical Trial
The SYNCHRONICITY clinical trial is a multicenter, open label trial evaluating YUTIQ in chronic inflammation. The SYNCHRONICITY clinical trial has enrolled 110 patient eyes in approximately 25 sites around the U.S. Patients who meet the entry criteria receive YUTIQ as an intravitreal injection in the designated study eye. The treatment period is 36 months, with data capture for this clinical trial being the first 24 months of YUTIQ drug treatment.
The primary outcome measure for the SYNCHRONICITY clinical trial is the mean change from baseline in BCVA letter score in the study eye measured by EDTRS at Month 6 and the mean change from baseline central subfield thickness at Month 6. Key secondary endpoints include time to recurrence of non-infectious inflammation in the study eye, presence of vascular leakage at Months 1, 3, 6, 12, 18, and 24, proportion of subjects with resolution of macular edema at Months 1, 3, 6, 12, 18, and 24, mean change from baseline in BCVA letter score at Day 14 and at Months 1, 3, 12, 18, and 24, and mean change from baseline in CST at Months 1, 3, 12, 18, and 24. The company expects to share the preliminary topline results of the SYNCHRONICITY clinical trial data in the first half of 2025.
Brands
The company has grown its brands portfolio of product offerings through acquisition. It has acquired the NDAs for and markets Atacand, Atacand HCT, Arimidex, Casodex, Lithobid, Vancocin, Inderal LA, Inderal XL, InnoPran XL, Oxistat, and Veregen. The company is innovating in its go-to-market strategy through creative partnerships and a sales force for these products.
Competitive Generic Therapy
The FDA Reauthorization Act of 2017 (‘FDARA’) created a new pathway by which FDA may, at the request of the applicant, designate a drug with ‘inadequate generic competition’ as a competitive generic therapy (‘CGT’). At the request of the applicant, the FDA may also expedite the review of an ANDA for a drug designated as a CGT. Under the CGT pathway, the FDA provides a statutory provision for a 180-day exclusivity period for certain first to market applicants whose ANDA received a CGT designation. The company’s Novitium subsidiary has developed a strong track record of obtaining CGT approvals and the company expects to continue to develop generic drugs under the CGT pathway.
Products
A complete list of the company’s generic and branded pharmaceutical products and descriptions is posted on its website, www.anipharmaceuticals.com.
Manufacturing, Suppliers, and Raw Materials
Several of the company’s key products, including injectables, softgel capsules, and Cortrophin Gel, as well as ILUVIEN and YUTIQ, are products that are currently manufactured and supplied by third parties, in some cases as a single source.
For instance, the company’s supply agreement for YUTIQ (the ‘YUTIQ Supply Agreement’) with EyePoint has an initial term of two years through May 2025. On February 27, 2025, the Company received written notice of non-renewal from EyePoint of the YUTIQ Supply Agreement, effective May 31, 2025. The Company has submitted a Prior Approval Supplement (‘PAS’) to the FDA seeking to add YUTIQ’s indication of chronic NIU-PS to the ILUVIEN label. The Company expects FDA approval of the PAS in the second quarter of 2025 and plans to market ILUVIEN for chronic NIU-PS in addition to its current indication of DME in the U.S. For reference, ILUVIEN is already approved and marketed for DME and NIU-PS outside the U.S., including in 17 European countries and the Middle East. In order to support the transition to ILUVIEN, in July 2024, the Company extended its partnership with Alliance Medical Products, Inc., a subsidiary of Siegfried Holding AG (‘Siegfried’), its long-term supplier for ILUVIEN, through 2029, and contracted with Siegfried to upgrade equipment on the existing manufacturing line and significantly expand capacity through the addition of a second manufacturing line.
Branded and Generic Pharmaceutical Products
The company’s facilities, procedures, operations, and testing of products are subject to periodic inspection by the FDA, the DEA, and other authorities. In addition, the FDA conducts pre-approval and post-approval reviews and plant inspections to determine whether the company’s systems and processes are in compliance with NDA and ANDA specifications, cGMP and other FDA regulations.
Controlled Substances
The DEA regulates certain drug products containing controlled substances, pursuant to the U.S. Controlled Substances Act (“CSA”). Certain of the company’s products contain significant components that are classified as controlled substances. CSA and DEA regulations impose specific requirements on manufacturers and other entities that handle these substances, including registration, recordkeeping, reporting, storage, security, and distribution.
In addition, the company must submit a request to the DEA for a quota to purchase the amount of API needed to manufacture certain of its products deemed controlled substances.
Medicaid/Medicare
Medicaid and Medicare, both of which are the U.S. federal health care programs administered by CMS, are major payors of pharmaceutical products, including those the company produces.
Patents, Trademarks, and Licenses
As of December 31, 2024, the company owned two U.S. patents, as well as pending patent applications relating to Cortrophin Gel. In addition, as a result of the Alimera acquisition in September 2024, the company acquired rights to two U.S. utility patents covering ILUVIEN and YUTIQ, as well as foreign counterparts to an expired U.S. design patent covering the ILUVIEN injector. The company licenses one utility patent right relating to the YUTIQ injector from EyePoint. Pursuant to an amended and restated license agreement (the "New Collaboration Agreement") with EyePoint, the company’s ILUVIEN-related patent rights are only for diseases of the human eye in Europe, the Middle East, and Africa; and for diseases of the human eye excluding uveitis in the rest of the world. Pursuant to a product rights agreement (Product Rights Agreement) entered into with EyePoint in May 2023, these rights have been expanded to include uveitis worldwide except for China and certain other countries in Asia.
The U.S. utility patents generally have a term of 20 years from the date of filing. The utility patent rights relating to ILUVIEN that EyePoint licensed to the company includes one U.S. patent that will expire in August 2027. An additional licensed patent relating to the YUTIQ injector will expire in January 2028.
In addition to Cortrophin Gel, ILUVIEN and YUTIQ, the company owns the trademark names for most of its branded products, including Cortenema, Cortrophin-Zinc, Inderal LA, Inderal XL, InnoPran XL, Kionex, Lithobid, SOVUNA, Reglan, Vancocin, and Veregen. The company licenses the trademark names for Atacand, Atacand HCT, Arimidex, Casodex, and Oxistat.
With the exception of a license for patent technology for Inderal XL, InnoPran XL, and Veregen, the company does not license any patents associated with these products. Furthermore, patent protection and market exclusivity for some of these branded products have expired, with the exception of the Veregen product, which has three patents. One patent expired in 2022 and the remaining two patents expire in 2025 and 2026. The company also recently acquired certain patents and patent applications relating to baclofen and a patent was granted on its hydrochlorothiazide product.
Distribution Agreements
In addition to selling products under the company’s own NDAs and ANDAs, the company enters into marketing and distribution agreements with third parties in which the company sells products under ANDAs or NDAs owned or licensed by these third parties. These products are sold under the company’s own label.
Customers
The company's customers purchase and distribute its products. Its customers include major national wholesalers. The company's products are sold by major retail pharmacy chains, distributors, national mail order houses, as well as group purchasing organizations.
For the year ended December 31, 2024, approximately 64% of the company’s net revenues were attributable to four customers. In addition, the company’s customers distribute its products.
Due to strategic partnerships between wholesalers and pharmacy chains, the company has experienced, and expects to continue to experience, increases in net sales to the wholesalers, with corresponding decreases in net sales to the pharmacy chains.
In the Rare Disease business, specifically for Cortrophin Gel, there is a limited distribution network and a select group of specialty pharmacies which can dispense product to appropriate patients. The company contracts and engages with the largest health insurance payers across the appropriate channels and classes of trade. For ILUVIEN and YUTIQ, its sales personnel focus on physician offices, clinics, pharmacies and hospitals in the U.S. and in European countries where the company seeks to engage end users to purchase its products.
Sales, Marketing, and Distribution
The company markets, sells, and distributes its products in the United States. The company’s products are distributed through the following channels:
Wholesalers: The company conducts business with the three major wholesalers in the United States: Cencora, Inc., Cardinal Health, and McKesson.
Retail Market Chains: The company conducts business with all the major retail chains in the United States, which include CVS, Rite Aid, Kroger, Walmart, and Walgreens.
Distributors and Specialty Pharmacies: The company has contracts with several major distributors and specialty pharmacies in the United States, including Anda, Smith Drug Company, Morris Dickson, CVS Caremark, Accredo, OptumRx, and CuraScript. It also has various agreements with international distributors for its ILUVIEN product.
Group Purchasing Organizations: The company has contracts with group purchasing organizations in the United States, such as ClarusONE, Walgreens Boots Alliance Development Group, Red Oak Sourcing, Econdisc, Optisource, Rx Sourcing Strategies, The Premier Group, Topco, The Buyer’s Consortium, Managed Health Care Associates Inc., Asembia, Premier Inc., and Kaiser Permanente.
Specialty Pharmacies: In its Rare Disease and Brands segment, the company contracts with specialty pharmacies.
Hospitals, Clinics, and Physicians: In its Rare Disease and Brands segment, specifically for ILUVIEN and YUTIQ, the company contracts with certain hospital systems, clinics, and physician offices.
Competition
Principal competitors for the Generic pharmaceutical markets in which the company does business include, but are not limited to:
Amneal Pharmaceuticals, Inc., Apotex Inc., Aurobindo Pharma, Camber Pharmaceuticals Inc., Hikma Pharmaceuticals plc, Lupin Pharmaceuticals, Inc., Rising Pharmaceuticals, Inc., Strides Pharma Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals USA, Inc., Viatris Inc., and Zydus Pharmaceuticals USA.
The principal competitor for Cortrophin Gel is Acthar Gel marketed by Mallinckrodt Pharmaceuticals.
The principal competitors for ILUVIEN and YUTIQ are:
DME Competitors: Eylea (aflibercept) 4 mg and Eylea HD (aflibercept) 8 mg, marketed by Regeneron in the U.S. and by Bayer in the EEA; Vabysmo (faricimab-svoa), marketed by Genentech; Avastin (bevacizumab), Lucentis (ranibizumab injection), marketed by Genentech (Roche) in the U.S. and Novartis in the rest of the world; Ozurdex (dexamethasone intravitreal implant), marketed by Allergan, an AbbVie company.
NIU-PS Competitors: Ozurdex (dexamethasone intravitreal implant), marketed by Allergan, an AbbVie company; Xipere (triamcinolone acetonide injectable suspension 40 mg/ml) marketed by Bausch & Lomb; Retisert, marketed by Bausch and Lomb; Humira© (adalimumab), marketed by AbbVie.
Trademarks
Cortenema, Purified Cortrophin Gel, Inderal LA, ILUVIEN, Inderal XL, InnoPran XL, Kionex, Lithobid, Reglan, SOVUNA, Vancocin, Veregen, and YUTIQ are registered trademarks subject to trademark protection and are owned by the company and its consolidated subsidiaries. Cortrophin-Zinc is a trademark owned by the company and its consolidated subsidiaries pending registration. Atacand and Atacand HCT are the property of AstraZeneca AB and are licensed to the company for the U.S. sales of those products. Arimidex and Casodex are the property of AstraZeneca UK Limited and are licensed to the company for the U.S. sales of those products. Oxistat is the property of Fougera Pharmaceuticals Inc. and licensed to the company for the U.S. sales of Oxistat Lotion.
Research and development
The company’s research and development costs totaled $44.6 million for the year ended December 31, 2024.
History
ANI Pharmaceuticals, Inc. was founded in 2001. The company was incorporated in 2001.
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.
